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Summary
Objective: While the interpretation of cartilage ﬁndings on magnetic resonance imaging (MRI) evolves, plain radiography remains the standard
method for assessing progression of knee osteoarthritis (OA). We sought to describe factors that explain variability in published estimates of
radiographic progression in knee OA.
Design: We searched PubMed between January 1985 and October 2006 to identify studies that assessed radiographic progression using
either joint space narrowing (JSN) or the KellgreneLawrence (KeL) scale. We extracted cohort characteristics [age, gender, and body
mass index (BMI)] and technical and other study factors (radiographic approach, study design, OA-related cohort composition). We performed
meta-regression analyses of the effects of these variables on both JSN and KeL progression.
Results: Of 239 manuscripts identiﬁed, 34 met inclusion criteria. The mean estimated annual JSN rate was 0.13 0.15 mm/year. While we
found no signiﬁcant association between JSN and radiographic approach among observational studies, full extension was associated with
greater estimated JSN among randomized control trials (RCTs). Overall, observational studies that used the semi-ﬂexed approach reported
greater JSN than RCTs that used the same approach. The overall mean risk of KeL progression by at least one grade was 5.6 4.9%, with
higher risk associated with shorter study duration, OA deﬁnition (KeL 2 vs KeL 1) and cohorts composed of subjects with both incident
and prevalent OA.
Conclusion: While radiographic approach and study design were associated with JSN, OA deﬁnition, cohort composition and study duration
were associated with risk of KeL progression. These ﬁndings may inform the design of disease modifying osteoarthritis drug (DMOAD) trials
and assist clinicians in optimal timing of OA treatments.
ª 2007 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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Osteoarthritis (OA) affects more than 21 million people in
the USA1, with 36% of elderly Americans aged 70 or older
having some degree of radiographic knee OA2,3. The prev-
alence of OA continues to grow as the population ages.
Currently available medications for knee OA ameliorate
pain without slowing structural progression associated
with the disease. Disease modifying osteoarthritis drugs
(DMOADs) are still in early stages of development and test-
ing4. In this era of active work on DMOAD development, it is1Support: National Institute of Arthritis and Musculoskeletal and
Skin Diseases (NIAMS) RO1 AR 053112, K24 AR 02123.
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873critical to determine the expected ‘natural history’ rate of
structural knee OA progression, as this is a key parameter
that could be affected by disease modifying therapy.
Magnetic resonance imaging (MRI) may eventually
eclipse plain radiography as the modality of choice for doc-
umenting structural progression in OA. However, the inter-
pretation of cartilage ﬁndings on MRI is still evolving and
plain radiography remains the standard method for assess-
ing progression. The measurement of radiographic joint
space width is the most accepted and widely used method
of assessing OA progression. As it has been shown to be
sensitive to change5, joint space narrowing (JSN) has re-
mained the primary outcome by which DMOAD trials
have tested drug efﬁcacy so far6,7. Yet, the rate of JSN
among cohorts with knee OA exhibits variability8e10, poten-
tially stemming from differences caused by changing pa-
tient characteristics and clinical status over time,
inconsistent radiographic positioning of the knee during se-
rial X-ray visits, and other technical factors8. With the
874 P. S. Emrani et al.: Joint space narrowing and KeL progression in knee OApromise of effective DMOAD therapy on the horizon, it is
crucial to establish factors affecting the rate of JSN across
various study settings.
Another common metric of OA progression is the
KellgreneLawrence (KeL) scale, traditionally used to as-
sess the severity of radiographic knee OA. This categorical
scale incorporates important radiographic features of OA
(JSN and osteophyte development) into one scale of in-
creasing severity11. The use of the KeL scale has been crit-
icized because its individual categories are not equidistant
from each other12. Consequently, estimates of the propor-
tion of patients that progress from one category to the
next may not be comparable for all starting points. Since
the KeL scale is still used in clinical settings for making
treatment decisions, its value in assessing knee OA pro-
gression warrants continued investigation.
The goal of this analytic review is to describe the variabil-
ity in estimates of knee OA progression (JSN and KeL)
from the published literature and to identify factors explain-
ing this variability. The potential predictors we examined in-
cluded study and technical factors (study design, year of
study publication, study duration, sample size, reader reli-
ability assessment, radiographic deﬁnition of OA, radio-
graphic approach used), and cohort characteristics [age,
gender, body mass index (BMI), baseline joint space width,
and OA-related cohort composition].MethodsSEARCH STRATEGYWe conducted a search of the PubMed database for relevant studies pub-
lished between January 1985 and October 2006. We used the key words OA
and knee, in combination with one or more of the following: progression (or
change), radiograph (or X-ray), JSN and KeL. The ﬁrst author screened
through abstracts identiﬁed by the search. For abstracts that assessed
JSN, we included for further review those studies in which the patient sample
had evidence of knee OA, progression was assessed radiographically over
time, and sample size was greater than 10. For abstracts that assessed
JSN, we included studies in which the patient sample had evidence of
knee OA, progression was assessed radiographically over time, and sample
size was greater than 10. Abstracts that analyzed KeL progression and ex-
amined OA incidence were also eligible for inclusion. We excluded literature
reviews and studies not published in English. For abstracts that passed this
screening, we retrieved the full length articles. For inclusion in our study, the
manuscript had to report either change in joint space width over a speciﬁed
period of time or the proportion of the population that progressed in KeL
grade over a speciﬁed period. Studies that exclusively assessed osteophyte
progression, used categorical scales of OA severity other than KeL, and re-
ported proportion of population that experienced JSN (rather than differences
in means) were excluded.DATA EXTRACTIONWe extracted the following study and technical factors: study design
[observational or randomized control trial (RCT)], year of publication, whether
radiograph reader reliability tests were conducted or cited, sample size,
length of follow-up, and radiographic view used. Year of publication was in-
cluded to address potential secular trends in radiographic methods. Radio-
graphic views included: standing antero-posterior (AP), metatarsal
phalangeal (MTP), ﬁxed-ﬂexion postero-anterior (PA), semi-ﬂexed AP, and
Lyon Schuss. We also extracted descriptive characteristics of the study pop-
ulation, including proportion female, mean age, mean BMI and mean base-
line joint space width (deﬁned as the smallest interbone distance across the
knee joint)6. We deﬁned three cohort types based upon the deﬁnition of dis-
ease: incident OA (no disease at baseline and progression to any higher
KeL grade), prevalent OA (disease at baseline and progression to any
higher KeL grade at follow-up), and ‘combination’, which included subjects
with both incident and prevalent OA (progression to any higher KeL grade,
irrespective of grade at baseline). We also extracted data pertinent to the two
main outcomes: (1) change in joint space width over the follow-up period and
(2) proportion of the study population that progressed at least one KeL grade
over the follow-up period. We refer to the latter as the risk of KeL
progression.ANALYSISDefinition of outcome variables
Estimates of change in joint space width over the follow-up period (re-
ferred to as JSN throughout this report) were converted to annual rates. Sim-
ilarly estimates for KeL progression were converted to annual risks of
progression. For studies that reported estimates of progression for multiple
cohorts, we included all estimates in our analyses. Thus, it was possible
for a given manuscript to report more than one progression estimate
(see Tables I and II). For studies that reported on change at various intervals
in the same patients, only the estimate from the longest follow-up time was
included. For RCTs, we extracted data from the placebo arm only. For stud-
ies that reported change in KeL scale in each (left, right) knee individually,
we used estimates for the right knee only.
Analysis of JSN
For the JSN analysis, we grouped the ﬁve radiographic approaches ob-
served in the literature into three categories: (1) full extension included the
standing AP view, (2) semi-ﬂexed with ﬂuoroscopy included the semi-ﬂexed
AP and Lyon Schuss views, and (3) semi-ﬂexed without ﬂuoroscopy included
the MTP and ﬁxed-ﬂexion PA views.
Analysis of progression in KeL grade
Since only one study assessing KeL progression used ﬂuoroscopic
methods, we collapsed the three radiographic approach categories to
include only full extension and semi-ﬂexed.
Three studies reported separate estimates of KeL progression when OA
was deﬁned as KeL 1 and KeL 2. To avoid double-counting these co-
horts, we ran two separate KeL models. Both models included all KeL esti-
mates from manuscripts that deﬁne OA either way, but not both. The ﬁrst
model included the estimates derived when OA was deﬁned as KeL 2
for these three studies. The second model included the three estimates
derived when OA was deﬁned as KeL 1.Statistical analysis
We performed meta-regression analyses examining the effects of radio-
graphic approach, study design, year of study publication, length of follow-
up, whether reader reliability was tested, and cohort characteristics such
as mean age and proportion female, on each outcome: JSN or KeL progres-
sion. In addition, for the JSN model, we included mean baseline joint space
width and mean BMI as predictors. For the KeL models, we included OA def-
inition and cohort composition. We then examined various hypothesis-driven
interactions in all models.
In both the JSN and KeL models, observations were weighted by the
sample size of the cohort from which the observation was derived. All statis-
tical analyses were performed at a 5% level of signiﬁcance using SAS statis-
tical software version 9.1 (SAS Institute, Cary, NC).Results
The results of the search are depicted in Fig. 1. Of 239
manuscripts identiﬁed through our PubMed search, 34
met both the inclusion criteria and did not meet the exclu-
sion criteria. These 34 studies comprise the study sample.
An overview of the characteristics of each of the included
studies is presented in Tables I and II.JSN PROGRESSIONCrude analysis
Of the 27 estimates that assessed JSN, 85% included
some measure of reader reliability. Sample sizes ranged
from 11 to 312, with a mean of 103 81 subjects across
all study groups under consideration. All studies had
a greater proportion of females than males. Length of fol-
low-up ranged from 8 to 72 months with a mean of 26 16
months. Fifteen estimates were derived from RCTs, and
the remaining 12 were derived from observational studies.
Eleven out of 27 estimates used full extension radiographic
approach; eight used semi-ﬂexed approach without
Table I
Study characteristics of the reviewed manuscripts: JSN
Author, year (Ref.) Study population Study
design
Reliability Sample
size
Female
(%)
Mean age
(years)
Mean
BMI
Baseline
JSW (mm)
Follow-up
(months)
Radiographic
approach
Annual rate
JSN (mm/year)
Bingham et al., 200621 Trial of oral
risedronate at 42 centers
in North America
RCT Yes 310 57 60.2 30.4 2.95 24 SFþ ﬂuoro 0.04
Trial of oral
risedronate at 44
European centers
RCT Yes 312 83 63.6 29.5 2.98 24 SFþ ﬂuoro 0.07
Brandt et al., 200522 Trial of doxycycline
in obese women
RCT Yes 180 100 55.0 36.7 3.60 30 SFþ ﬂuoro 0.18
Buckland-Wright et al., 199523 Trial of diclofenac sodium RCT Yes 34 73 65.5 NA 3.20 18 SF ﬂuoro 0.09
Cicuttini et al., 200524 Clinic-based and
community-based cohort
Obs Yes 28 63 62.8 28.6 7.87 23 Extension 0.24
Cline et al., 200625 DMOAD Roche trial RCT No 99 69 59.0 30.0 3.79 8 SF ﬂuoro 0.10
DMOAD Bayer trial RCT No 112 67 63.0 NA 3.27 10 SF ﬂuoro 0.00
DMOAD Procter & Gamble trial RCT No 85 64 63.0 29.1 3.07 12 SFþ ﬂuoro 0.12
Conrozier et al., 200526 Clinic-based cohort Obs Yes 73 68 60.9 NA 4.10 12 SF ﬂuoro 0.19
Dieppe et al., 199727, * Clinic-based cohort, lateral
compartment
Obs Yes 145 67 62.6 26.9 NA 36 Extension 0.07
Clinic-based cohort,
medial compartment
Obs Yes 145 67 62.6 26.9 NA 36 Extension 0.10
Gandy et al., 200228 Clinic-based cohort Obs Yes 11 60 63.4 28.4 4.71 37 Extension 0.07
Listrat et al., 199729 Trial of intra-articular
injections of hyaluronan
RCT No 17 79 64.0 26.6 3.50 12 Extension 0.70
Michel et al., 200530 Trial of chondroitin sulfate RCT Yes 150 52 63.1 28.1 2.45 24 SF ﬂuoro 0.04
Miyazaki et al., 200231 Clinic-based cohort Obs Yes 74 78 69.5 24.5 3.30 72 SF ﬂuoro 0.23
Pavelka et al., 200432 Clinic-based cohort Obs Yes 89 66 56.7 28.6 4.95 24 Extension 0.20
Pavelka et al., 200010 Trial of glycosaminoglycan
polysulphuric acid complex
RCT Yes 139 76 59.1 31.5 3.92 60 Extension 0.08
Pavelka et al., 200233 Trial of glucosamine sulfate RCT Yes 101 70 63.5 30.0 3.63 36 Extension 0.06
Pessis et al., 200334 Clinic-based cohort Obs No 20 65 63.0 30.0 3.80 12 Extension 0.10
Clinic-based cohort Obs No 20 65 63.0 30.0 2.80 12 SFþ ﬂuoro 0.0
Raynauld et al., 200335 Trial of long-term intra-articular
steroid injections
RCT No 34 61 63.3 31.9 3.93 24 SFþ ﬂuoro 0.04
Reginster et al., 200136 Clinic-based cohort RCT Yes 71 77 65.3 27.2 4.01 36 Extension 0.13
Sharma et al., 200137 Community-based cohort Obs Yes 230 75 64.0 30.3 NA 18 SFþ ﬂuoro 0.30
Spector et al., 200538 BRISK trial of risedronate RCT Yes 80 65 63.2 29.2 3.03 12 SF ﬂuoro 0.12
Sugiyama et al., 200339 Community-based cohort
of rural village in Japan
Obs Yes 110 100 50.2 24.7 3.40 48 SFþ ﬂuoro 0.13
Uebelhart et al., 200440 Trial of oral chondroitin sulfate RCT Yes 76 82 63.7 29.0 3.65 12 Extension 0.32
Vignon et al., 200315 NA Obs Yes 32 75 68.8 NA 2.92 24 SF ﬂuoro 0.12
Obs, observational cohort; SFþ ﬂuoro, semi-ﬂexed with ﬂuoroscopy; SF ﬂuoro, semi-ﬂexed without ﬂuoroscopy; NA, data not available from manuscript.
*Estimates of progression may include knees without OA. Analysis reported separate mean JSN estimates in medial and lateral compartments of each knee in a cohort of patients with OA in
at least one knee. Right knee estimates are presented here.
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Table II
Study characteristics of the reviewed manuscripts: KeL progression
Author, year (Ref.) Study population Disease deﬁnition Study
design
Reliability Sample
size
Female
(%)
Mean age
(years)
Follow-up
(months)
Radiographic
approach
Risk of KeL
progression/year
Cohort composition KeL grade
Bagge et al., 199241 Community-based cohort Incident and prevalent 2 Obs Yes 74 57 75.0 48 Semi-ﬂexed 0.043
Bergink et al., 200542 Rotterdam study Incident only 2 Obs Yes 1115 59 66.3 79.2 Semi-ﬂexed 0.010
Rotterdam study Prevalent only 2 Obs Yes 288 59 66.3 79.2 Semi-ﬂexed 0.014
Cooper et al., 200019, * Survey population Incident only 2 Obs Yes 242 72 75.8 61.2 Extension 0.040
Survey population Prevalent only 2 Obs Yes 112 72 75.8 61.2 Extension 0.038
Survey population Incident only 1 Obs Yes 178 72 75.8 61.2 Extension 0.035
Survey population Prevalent only 1 Obs Yes 176 72 75.8 61.2 Extension 0.064
Felson et al., 199543,* Framingham study Incident only 2 Obs Yes 381 100 70.8 97.2 Extension 0.024
Framingham study Incident only 2 Obs Yes 217 0 70.8 97.2 Extension 0.014
Framingham study Prevalent only 2 Obs Yes 170 100 70.8 97.2 Extension 0.046
Framingham study Prevalent only 2 Obs Yes 91 0 70.8 97.2 Extension 0.034
Lachance et al., 200244,* Michigan bone
health study and study
of women’s health
across the Nation
Incident only 1 Obs Yes 489 100 NA 30 Extension 0.125
Michigan bone
health study and study
of women’s health
across the Nation
Incident only 2 Obs Yes 605 100 NA 30 Extension 0.052
LaValley et al., 200145 Framingham study Incident and prevalent 1 Obs No 843 64 71.1 102 Extension 0.029
Ledingham et al., 199546 Clinic-based study Incident and prevalent 2 Obs Yes 350 63 71.1 27.1 Extension 0.196
Mazzuca et al., 200647 Trial of doxycycline,
obese women
Prevalent only 2 RCT Yes 431 100 55.0 30 Semi-ﬂexed 0.095
Pavelka et al., 200010 Trial of glycosaminoglycan
polysulphuric acid complex
Prevalent only 1 RCT Yes 139 76 59.1 60 Extension 0.042
Reijman et al., 200548,y Rotterdam study Incident and prevalent 1 Obs Yes 874 58 66.0 79.2 Extension 0.045
Spector et al., 199249 Clinic-based and those
enrolled in drug study
Incident and prevalent 1 Obs Yes 63 76 69.0 132 Extension 0.043
Spector et al., 199450 Chingford study Prevalent onlyy 2 Obs No 58 100 56.8 24 Extension 0.119
Spector et al., 199751 Chingford study Prevalent only 2 Obs Yes 70 100 56.0 48 Extension 0.136
Obs, observational cohort; NA, data not available from manuscript.
*Cohort characteristics (mean age, % female) based on entire patient sample (Cooper, n¼ 354; Felson, n¼ 869; Lachance, n¼ 679).
yIncident total knee replacement (TKR) included in deﬁnition of progression.
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877Osteoarthritis and Cartilage Vol. 16, No. 8ﬂuoroscopy; and eight used semi-ﬂexed approach with ﬂuo-
roscopy (see Fig. 2). JSN estimates ranged from 0.10 (in-
dicating an increase in joint space width over time) to
0.70 mm/year. The mean annual JSN across all estimates
was 0.13 0.15 mm/year.
Multivariate findings
Overall, observational studies had a mean rate of JSN of
0.17 mm/year [95% conﬁdence interval (CI), 0.11e0.22],
compared with 0.08 mm/year (95% CI, 0.04e0.12) for RCTs
(see Fig. 2), adjusting for radiographic approach, follow-up
time, and gender. The effect of radiographic approach
depended on study design (P for interaction¼ 0.02) (see
Fig. 2). Adjustedmean rates of JSNwere similar for full exten-
sion across both study designs (0.13 mm/year for observa-
tional studies and 0.18 mm/year for RCTs). Observational
studies that used either semi-ﬂexed approach reported larger
narrowing estimates compared to RCTs that used the
sameapproach.Wedidnot ﬁnda statistically signiﬁcant asso-
ciation between radiographic approach and JSN among
observational studies. However, among RCTs, full extension
was associatedwith greater narrowing compared to the semi-
ﬂexedwithout ﬂuoroscopyapproach.We foundnostatistically
signiﬁcant difference in narrowing between full extension and
semi-ﬂexed with ﬂuoroscopy among RCTs, but the minimal
overlap inCIsbetween the twogroups is suggestiveof adiffer-
ence (see Fig. 2).239 abstracts
identified through
PubMed and
screened
134 abstrac
excluded
105 articles
reviewed (44%)
71 articles
excluded
34 articles
included in review
(14%)
12 (5%) Kellgren-
Lawrence studies
21 (9%) joint
space narrowing
studies
1 (0.4%) both
space narrow
and Kellgre
Lawrence
Fig. 1. Manuscript search aWe found a suggestive negative linear relationship
(b¼0.0025, P¼ 0.06) between JSN and longer follow-
up time [see Fig. 4(A)]. Our data did not provide evidence
of a linear relationship between JSN estimates and gender
(b¼0.0020, P¼ 0.16). We did not ﬁnd an association be-
tween rates of JSN and mean age, mean BMI, reader reli-
ability, and year of publication. Baseline joint space width
was highly correlated with study design and radiographic
approach, and thus was not included in the ﬁnal model.KeL PROGRESSIONCrude analysis
Of the 18 estimates of KeL progression derived from
the literature, 89% included some measure of reader reli-
ability. Sample sizes ranged from 58 to 1115 with a mean
of 334 314 subjects. All studies had a greater proportion
of females than males. Length of follow-up varied from
24 to 132 months with a mean of 69 31 months. Eleven
out of 13 studies were observational studies, and the re-
maining two were RCTs. Ten out of 13 used full extension
radiographic approach, while the remaining three used
semi-ﬂexed approach. In our ‘KeL 2’ model, ﬁve esti-
mates were derived from OA deﬁnition KeL 1 and 13
from KeL 2. In our ‘KeL 1’ model, eight estimates
were derived from OA deﬁnition KeL 1 and 10 from
KeL 2. The annual estimates of progression by at leastts
Reasons for exclusion (# excluded):
--Study design not longitudinal (40)
--Surgical cohort (32)
--Review (19)
--Not human (19)
--Not exclusive knee OA cohort (13)
--Radiographic change over time not
reported (11)
 joint
ing
n
Reasons for exclusion (# excluded):
--Progression estimates not quantified (30)
--JSN not specified as continuous variable (22)
--Redundant cohort (5)
--Follow up duration not specified (4)
--Cohort not limited to radiographic OA
patients (3)
--Progression summarized in treatment arm
of RCT (2)
--Tibio-femoral cartilage loss not measured(2)
--Selection bias (2)
--Atypical sample, twin study (1)
nd selection process.
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Fig. 2. Annual JSN stratiﬁed by study design and radiographic approach. Circles represent individual mean JSN estimates. Circle area is pro-
portional to sample size of corresponding cohort. Means within study design and radiographic approach sub-categories are depicted in gray.
Overall means within each study design category and the overall mean for all estimates are depicted in black. The means are displayed above
corresponding circles, with error bars representing 95% CIs. Each study reference is denoted next the circle, representing the corresponding
manuscript from which the progression estimate was derived. An estimate of 0.7 mm/year29 (RCT, full extension) is not shown for scaling
purposes.
878 P. S. Emrani et al.: Joint space narrowing and KeL progression in knee OAone KeL grade ranged from 1.0 to 19.6%, with an overall
mean risk of progression of 5.6 4.9%.Multivariate findings
Main analysis: ‘KeL 2’ model. Risk of KeL progression
was associated with a shorter follow-up time (b¼0.0010,
P< 0.01) and with cohort composition (P< 0.01). We found
a suggestive association between KeL progression and OA
deﬁnition (P¼ 0.09). Studies with ‘combination’ cohorts
(subjects with both incident and prevalent OA) had a greater
risk of progression than those studies with incident or prev-
alent cohorts alone [8.0 vs 2.4% (P< 0.01) and 3.9%
(P¼ 0.05), respectively] (see Fig. 3). Studies that deﬁned
OA as KeL 2 had a greater risk of progression than those
studies that deﬁned OA as KeL 1 (6.2 vs 3.3%). As seen
in Fig. 4(B), a negative linear relationship exists between risk
of KeL progression and follow-up time. We did not ﬁnd an
association between KeL progression and radiographic
approach, gender, age, year of publication, study design,
or reader reliability.
Sensitivity analysis: ‘KeL 1’ model. We repeated the KeL
model with the estimates derived from OA deﬁned as Ke
L 1 instead of from KeL 2 for the three studies that
presented both, in order to assess the sensitivity of the
model to OA deﬁnition. Multivariate ﬁndings were similar in
both models, except for the effect of radiographic approach.
In the KeL 1 model, studies using full extension hada greater adjusted risk of progression than those using
semi-ﬂexed approach (7.0 vs 3.6%, P< 0.01).Discussion
The goal of this analytic review was to describe the vari-
ability in estimates of knee OA progression (JSN and KeL)
from the published literature and to identify factors explain-
ing this variability. We performed a thorough systematic
search and analytic synthesis of the published peer-re-
viewed literature on radiographic progression of knee OA.
Using these sources, we derived estimated annual rates
of JSN and risks of KeL progression in populations with
knee OA. We used meta-regression to study the associa-
tion of these measures of OA structural progression with co-
hort characteristics and study features, in an attempt to
explain the variability in estimates. A better understanding
of the true rate of progression would assist clinicians in pro-
viding patients with an evidence-based trajectory of disease
and timing of appropriate treatments. These estimates may
also inform research on the development and testing of
DMOADs.
We found a mean rate of JSN of 0.13 0.15 mm/year
across all estimates. This value falls within the range re-
ported by other investigators. Pavelka et al. reported
annual rates of progression of JSN of 0.06e0.60 mm/
year10. Our ﬁnding is also consistent with the range re-
ported by Vignon et al. of 0.10e0.15 mm/year in hip and
knee joints6. Secondly, we found a mean annual risk of pro-
gression in KeL grade of 5.6 4.9%. To the best of our
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Fig. 3. Annual risk of KeL progression stratiﬁed by cohort composition. Circles represent individual estimates of the proportion of the cohort
that progressed by at least one KeL grade per year of follow-up time. Circle area is proportional to sample size of corresponding cohort.
Means within each cohort composition category are depicted in gray. Overall mean for all reviewed KeL studies is depicted in black. The
means are displayed above corresponding circles, with error bars representing 95% CIs. Each study reference is denoted next the circle, rep-
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879Osteoarthritis and Cartilage Vol. 16, No. 8knowledge there are no published reports summarizing OA
progression based on KeL grade. Both metrics exhibited
variability, with standard deviations similar to the means.
This is the ﬁrst literature review to our knowledge that
comprehensively reports OA progression estimates and at-
tempts to quantitatively explain the variability inherent in
these estimates, adjusting for important covariates. To rig-
orously investigate these questions, we also used weighted
regression techniques, which helped to eliminate the effect
of sample size on the parameter estimates.
We demonstrated that estimates of JSN exhibit variabil-
ity, partly explained by differences in radiographic approach
and study design (see Fig. 2). We found that among obser-
vational studies, those that used full extension approach,
while not statistically signiﬁcant, tended to report lower esti-
mates of narrowing than those that used either semi-ﬂexed
approach. This is consistent with ﬁndings by Wolfe et al.,
who reported that, in a clinic-based observational cohort,
greater narrowing was seen in Lyon Schuss semi-ﬂexed
view (uses ﬂuoroscopy) and MTP semi-ﬂexed view (no ﬂuo-
roscopy) when both were compared to standing AP view
(full extension). No difference was reported between the
Lyon Schuss view and the MTP view, further supporting
our ﬁnding that the use of ﬂuoroscopy in the semi-ﬂexed ap-
proach has little impact on the JSN estimates (see Fig. 2)13.
Recently, a shift toward non-ﬂuoroscopic methods has oc-
curred because they are less costly and easier to use,
with little tradeoff in imaging quality and reproducibility14.
Overall, full extension exhibited greater variability compared
with both semi-ﬂexed methods. Variability in serial radio-
graphs in full extension may result from differences in
knee positioning or changes in pain status at repeated
X-ray visits, as patients with OA may be unable to adopt
the fully extended position due to a joint pain ﬂare6. Semi-
ﬂexed views employ various methods to standardize knee
positioning and foot rotation to minimize variability. Such
methods include MTP and patella alignment with ﬁlmcassette (MTP semi-ﬂexed)13, X-ray beam angulation in
line with medial tibial plateau (Lyon Schuss semi-ﬂexed
view)15, and ﬂuoroscopy.
The lower mean narrowing observed among subjects par-
ticipating in RCTs utilizing either semi-ﬂexed approach may
suggest systematic differences in selection criteria for
RCTs as compared to observational studies. Trials tend to
set more stringent inclusion and exclusion criteria, resulting
in a more homogeneous population. Moreover, the popula-
tions that participate in RCTs and observational studies
may differ according to other important and unmeasured con-
founders, potentially resulting in the observed differences.
RCTs may also be better funded to obtain radiographs of
consistent method, quality, and timing. However, while
RCTs are the best approach to testing efﬁcacy questions,
their samples are selected and typically are not as generaliz-
able to clinical populations as observational studies.
The variability in progression along the KeL scale was
explained in part by differences in follow-up time, OA deﬁni-
tion, and cohort composition [see Figs. 3 and 4(B)]. We
found that a higher risk of KeL progression was associated
with full extension in the KeL 1 model. The full extension
view of the knee may be optimal for visualizing osteophytes,
and thus may explain why a higher risk of KeL progression
was seen in those studies that used full extension view
compared with semi-ﬂexed view. This may also explain
why the majority of studies that reported KeL progression
employed full extension view. This is consistent with ﬁnd-
ings by Wolfe et al., who reported that standing AP (fully
extended) radiographs accumulated a greater mean osteo-
phyte score [OARSI (Osteoarthritis Research Society Inter-
national) atlas] compared to Lyon Schuss semi-ﬂexed
radiographs13. The differential ability of the two radiographic
approaches to show osteophytes may also explain why ra-
diographic approach did not matter in the analysis using
KeL 2 as the OA deﬁnition, but was signiﬁcantly associ-
ated with risk of progression when OA was deﬁned as
Fig. 4. Association of OA progression [JSN (A) and KeL (B)] and study duration. Circles represent individual estimates of the proportion of the
cohort that progressed by at least one KeL grade per year of follow-up time. Circle area is proportional to sample size of corresponding cohort.
Regression line for follow-up time is weighted for sample size and adjusted for radiographic approach (A and B), OA deﬁnition (B), and cohort
composition (B).
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phytes’’ (i.e., KeL¼ 1) than semi-ﬂexed. When OA is de-
ﬁned as KeL 2, it is possible that each radiographic
approach shows ‘‘deﬁnite osteophytes’’ equally well. How-
ever, it should be noted that sensitivity of the model to radio-
graphic approach may simply be due to the small number of
studies and estimates, resulting in a difference in only three
estimates affecting the signiﬁcance of the ﬁnding.
The difference in follow-up time seen in JSN studies and
KeL studies also warrants discussion. As seen in Fig. 4(A)
and (B), a negative linear relationship exists between both
JSN and risk of KeL progression and follow-up time. It is im-
portant to note that the mean follow-up time for JSN studies
was 26 months compared to 63 months for KeL studies.
The shorter duration of JSN studies precludes comparisons
across longer follow-up durations. The risk of KeL progres-
sion decreases as follow-up time increases, demonstratingthat progression of OA as measured by the KeL scale may
not be constant over time. This may reﬂect the biology of
OA progression, suggesting it may plateau. On the other
hand, this association may simply indicate that the KeL
scale is ordinal but not interval. KeL grades 1e2 track the
growth of osteophytes, while KeL grades 3e4 track JSN.
Since the two ends of the scale reﬂect different pathological
processes that involve different tissues, the amount of dis-
ease progression from one grade to the next should not
be considered equal throughout the scale12. There is also
a ceiling effect at KeL grade 4, since progression beyond
>50% narrowing cannot be captured. It is possible that lon-
ger studies tend to accumulate more patients with KeL
grade 4 who cannot progress any further along the scale,
resulting in slower rates of progression.
Our review had several limitations. First, we identiﬁed
several limitations in this literature which may have affected
881Osteoarthritis and Cartilage Vol. 16, No. 8our results. Across eligible studies, documented risk factors
for progressive knee OA were not universally reported. Risk
factors for knee OA progression include BMI, varusevalgus
alignment, dynamic load, concurrent OA in other joints,
synovitis, ligamentous laxity, and bone marrow edema
lesions16. BMI, in particular, has been conﬁrmed as a risk
factor for incident OA, but multiple studies have found that
BMI is only a weak predictor of JSN compared with radio-
graphic evidence such as initial joint space width or narrow-
ing17,18. We did not ﬁnd an association between mean BMI
and JSN. However, four studies did not report mean BMI,
limiting our capacity to see an effect. A majority of the re-
viewed KeL studies (8/13) did not report mean BMI of their
cohorts; thus we were unable to include this in the KeL
models. However, the literature suggests the effect of BMI
on our progression estimates would likely be modest19.
We focused our analyses on radiographic e not MRI e
progression of OA. We acknowledge that MRI is a powerful
modality for imaging the arthritic knee. However, the inter-
pretation of longitudinal changes in joint structures seen
on MRI is undergoing intensive discussion20 and assess-
ment of plain radiographs remains the most well accepted
approach to structural progression at present.
In addition, approximately 60% of the JSN manuscripts
limited their patient samples to those with KeL grades of
less than four or joint space width> 2 mm at baseline, while
none of the KeL manuscripts noted any exclusion of those
with advanced disease. Thus, narrowing estimates derived
from these studies may not be representative of the entire
OA population.
A better understanding of the true rate of progression
would assist clinicians in providing patients with an evi-
dence-based trajectory of disease and timing of appropriate
treatments. These estimates may also inform research on
the development and testing of DMOADs. In particular,
these data should help investigators estimate sample sizes
when designing DMOAD trials. Our data also support the
need for standardized radiographic protocols to assess
the progression of OA. The optimal protocol is one that is
sensitive to change, reproducible, accurate, and constant
across study settings and study populations. As there
may be tradeoffs in establishing a standard radiographic ap-
proach, this decision should be undertaken carefully with
involvement of a full complement of stakeholders.
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